Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Next Article in Journal
Chondroitin Sulfate-Based Imatinib Nanoparticles Targeting Activated Hepatic Stellate Cells Against Hepatic Fibrosis
Previous Article in Journal
Albumin-Based Nanoparticles with Factorial Design as a Promising Approach for Remodeled Repaglinide: Evidence from In Silico, In Vitro, and In Vivo Evaluations
Previous Article in Special Issue
Halloysite Nanotube-Based Delivery of Pyrazolo[3,4-d]pyrimidine Derivatives for Prostate and Bladder Cancer Treatment
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies

by
Jurga Bernatoniene
1,2,*,
Mindaugas Plieskis
3 and
Kestutis Petrikonis
4
1
Department of Drug Technology and Social Pharmacy, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50161 Kaunas, Lithuania
2
Institute of Pharmaceutical Technologies, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50161 Kaunas, Lithuania
3
SwissHealix GmbH, Gutsch 21, Allenwinden, 6319 Zug, Switzerland
4
Department of Neurology, Lithuanian University of Health Sciences, Eivenių str. 2, LT-50009 Kaunas, Lithuania
*
Author to whom correspondence should be addressed.
Pharmaceutics 2025, 17(3), 352; https://doi.org/10.3390/pharmaceutics17030352 (registering DOI)
Submission received: 7 February 2025 / Revised: 1 March 2025 / Accepted: 6 March 2025 / Published: 9 March 2025
(This article belongs to the Special Issue Applications of Nanomaterials in Drug Delivery and Drug Release)

Abstract

Pharmaceutical 3D printing, combined with nanomaterials and nanodevices, presents a transformative approach to precision medicine for treating neurological diseases. This technology enables the creation of tailored dosage forms with controlled release profiles, enhancing drug delivery across the blood−brain barrier (BBB). The integration of nanoparticles, such as poly lactic-co-glycolic acid (PLGA), chitosan, and metallic nanomaterials, into 3D-printed scaffolds improves treatment efficacy by providing targeted and prolonged drug release. Recent advances have demonstrated the potential of these systems in treating conditions like Parkinson’s disease, epilepsy, and brain tumors. Moreover, 3D printing allows for multi-drug combinations and personalized formulations that adapt to individual patient needs. Novel drug delivery approaches, including stimuli-responsive systems, on-demand dosing, and theragnostics, provide new possibilities for the real-time monitoring and treatment of neurological disorders. Despite these innovations, challenges remain in terms of scalability, regulatory approval, and long-term safety. The future perspectives of this technology suggest its potential to revolutionize neurological treatments by offering patient-specific therapies, improved drug penetration, and enhanced treatment outcomes. This review discusses the current state, applications, and transformative potential of 3D printing and nanotechnology in neurological treatment, highlighting the need for further research to overcome the existing challenges.
Keywords: 3D pharmaceutical printing; nanomaterials; nanodevices; neurological diseases 3D pharmaceutical printing; nanomaterials; nanodevices; neurological diseases

Share and Cite

MDPI and ACS Style

Bernatoniene, J.; Plieskis, M.; Petrikonis, K. Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies. Pharmaceutics 2025, 17, 352. https://doi.org/10.3390/pharmaceutics17030352

AMA Style

Bernatoniene J, Plieskis M, Petrikonis K. Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies. Pharmaceutics. 2025; 17(3):352. https://doi.org/10.3390/pharmaceutics17030352

Chicago/Turabian Style

Bernatoniene, Jurga, Mindaugas Plieskis, and Kestutis Petrikonis. 2025. "Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies" Pharmaceutics 17, no. 3: 352. https://doi.org/10.3390/pharmaceutics17030352

APA Style

Bernatoniene, J., Plieskis, M., & Petrikonis, K. (2025). Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies. Pharmaceutics, 17(3), 352. https://doi.org/10.3390/pharmaceutics17030352

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop